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Abstract
Treatment of ROP is currently evolving. Novel therapeutic options are emerging that have the
potential to complement existing therapies and improve treatment outcomes. However, any new
therapeutic options must be thoroughly evaluated before existing (and successful) treatment
paradigms can be amended. This is particularly so when switching from locally effective therapies
like photablative laser therapy to systemic pharmacologic treatments that may have hitherto
unknown widespread side effects. This review compiles the current knowledge of where and when
the two most advanced pharmacologic treatment options for ROP, IGF-1 supplementation and
anti-VEGF treatment, may have their place in future therapy regimens for ROP. The requirement
for clinical studies is emphasized: these are needed to address safety considerations before any of
these interventions can achieve the status of standard clinical care in the very vulnerable
population of ROP infants.
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Introduction
The term “retinopathy of prematurity” (ROP) was first coined in the late 1940s. ROP
replaced the earlier term “retrolental fibroplasia”, which described a complete retinal
detachment visible as a fibrotic mass directly behind the lens. Today, ROP is divided into 5
stages. Stage 5 is a completely detached retina seen in “retrolental fibroplasia”. Due to
advances in neonatal intensive care, rigorous ophthalmologic screening and adherence to
treatment guidelines, stage 5 ROP has become increasingly rare, as is stage 4 ROP with a
partially detached retina. The most common proliferative ROP stages seen in developed
countries today are stage 1 (demarcation line between vascularized and non-vascularized
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retina), stage 2 (prominent demarcation ridge between vascularized and non-vascularized
retina) and stage 3 (demarcation ridge with extraretinal proliferations).
The reason for less late stage retinal detachment is twofold. Improved NICU practices such
as oxygen control reduce disease burden as does ablation treatment. Most infants with ROP
are identified early by ophthalmologic screening to initiate treatment in time to avoid
progression to stage 4 or 5 ROP. In most countries, treatment criteria for ROP are adopted
from the ETROP study [1]. A treatment decision is based on ROP stage as well as the
tortuosity and dilation of retinal vessels and the zone of the affected retina. Physiologically,
the eye is vascularized from the optic nerve with radial progression to the periphery [2].
Figure 1 demonstrates this centrifugal pattern of retinal vessel growth in the mouse retina.
The earlier that normal retinal vascular development is disrupted by preterm birth, the
greater the area of unvascularized retina. This avascular tissue typically is quiescent for the
first weeks after birth while further retinal vessel growth is stalled. Later, (typically after 30–
32 weeks’ postmenstrual age (PMA)), as retinal photoreceptors mature and become
metabolically active, the avascular retina become hypoxic and secretes hypoxia-regulated
angiogenic growth factors like VEGF [4,5]. The greater the avascular area present, the
higher the levels of VEGF that induce pathological vascular growth - vessels growing into
the vitreous. To account for variable areas of avascular retina and the associated differences
in angiogenic growth factor production, ROP is divided into three zones. Zone I refers to
vascularized retina that lies within a circle around the optic nerve head (ONH) with a radius
of twice the distance from optic nerve head to fovea. Zone II is vascularized retina within a
circle around the ONH with the nasal curvature reaching the ora serrata (i.e. the nasal
peripheral edge of the retina). Zone III is the remaining crescent-shaped area in the temporal
part of the retina that remains outside zone II. Figure 2 summarizes the zones used for ROP
grading.
Following ETROP criteria, all stages of ROP require treatment when the border between
vascularized and unvascularized retina lies in zone I and “plus disease” is present. “Plus
disease” refers to the dilation and tortuosity of retinal vessels and is an important indicator
of disease activity. Vessel tortuosity in two or more clock hours at the posterior pole of the
eye is generally accepted as sufficient to add the suffix “plus” to a ROP stage, indicating
high disease activity. Unlike zone I, zone II ROP only requires treatment when stages 2 plus
or 3 plus are present. Zone III ROP rarely requires treatment; observation is usually
sufficient until full retinal vascularization is documented.
It should be noted that not all national guidelines fully follow the ETROP criteria. For
example the current German guidelines for treating ROP do not include ROP stage 2 plus in
zone II, because many of these infants may never develop a proliferative ridge [7]. The
German guidelines recommend tight ophthalmologic follow-up for stage 2 plus in zone II
and treatment only when vasoproliferation appears on the ridge (i.e. when progression to
stage 3 plus is noted over several clock hours of the retinal circumference in zone II).
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ROP treatment: cryo, laser and anti-VEGF therapy
Published in 1990, the CRYO-ROP study laid the foundation for ROP treatment [8,9]. The
main finding was that infants treated with cryoablation of avascular retina had fewer
unfavourable structural outcomes compared to non-treated infants. In the 1990s, laser
photocoagulation of avascular retina was introduced as a treatment alternative to
cryotherapy [10–12] and today, has replaced cryotherapy in most countries [13]. Both cryo
and laser therapy follow the same principle: avascular retina is destroyed in order to
decrease the production of pro-angiogenic growth factors from hypoxic retinal cells. The
treatment is safe and when performed properly in most cases stops disease progression
before stage 4 or 5 ROP develops. For those cases in which laser treatment is insufficient or
initiated too late and a retinal detachmet has already occurred, (or in cases where ROP
proceeds despite treatment), retinal surgery to re-attach the detached retina is warranted.
However, treatment results for late stages of ROP are often disappointing [14,15]. The goal
is to identify and treat infants before stage 4 or 5 ROP develops. The downside of laser
therapy, however, is that potentially viable retinal tissue is replaced with functionless scar
tissue.
For the last several years, anti-VEGF treatment has been used as an off-label alternative to
laser photocoagulation for ROP. The BEAT ROP results published in 2011, were the first
data from a multicenter randomized trial on anti-VEGF treatment in ROP [16]. The BEAT-
ROP study compared the effects of bevacizumab, an anti-VEGF antibody, to the effects of
conventional laser therapy. Recurrence of active ROP was the primary outcome. There are
several limitations to this study, one being the relatively short follow-up window precluding
complete evaluation of systemic and opthalmologic complications. Mean age for ROP
treatment was about 34–36 weeks PMA; the follow-up period was 20 weeks after treatment
or up to 54 weeks PMA. The BEAT-ROP study noted more ROP recurrences in the laser-
treated group compared to the bevacizumab-treated group only in zone I ROP. ROP
recurrence was similar for both therapies in infants with zone II ROP. Furthermore, the rate
of ROP recurrences in the laser group was high compared to other studies. In addition, other
reports note that ROP recurrences after bevacizumab treatment may occur much later than
after laser therapy – therefore potentially occuring outside the observational window of up to
54 weeks PMA in the BEAT-ROP study [17,18]. Despite these caveats, the BEAT ROP
results raised some important points: (i) bevacizumab is effective in halting neovascular
disease progression in ROP in most cases; (ii) unlike laser therapy, the avascular retinal
areas are not destroyed but may become (partially) vascularized over time. Whether the
vessels and underlying neural retina is normal is unknown. The BEAT ROP results have
thus introduced anti-VEGF treatment as a potential treatment option for ROP.
Nevertheless, some important questions remain. For example, there is currently only limited
long-term data on visual function following anti-VEGF treatment in ROP. With VEGF
being an important growth factor, not only for blood vessels but also for neuronal cells of
the retina, it is essential to gather more data on long-term functional outcomes in retina as
well as in other organs [19]. The available data to date suggest that visual function is not
significantly impaired compared to laser-treated eyes and the refractive error that is often
seen after laser treatment might be less in anti-VEGF treated eyes [20,21].
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Another pertinent question raised by the BEAT ROP study is when to end follow-up
examinations following anti-VEGF therapy. Like all other intravitreally administered drugs,
bevacizumab exits the eye over time via RPE? and choroidal vasculature leading to
decreasing levels of anti-VEGF drug in the eye [22]. If the peripheral retina is not yet fully
vascularized, there will be a potential source of excessive VEGF that may over time exceed
the amount of remaining anti-VEGF drug in the eye leading to re-activation of ROP. Since
both the kinetics of VEGF expression in avascular retina and the rate of peripheral
vascularization will be different between individuals, there may not be a general rule as to
how long and how frequently these infants will need to be followed after intravitreal anti-
VEGF therapy. A relatively safe situation is reached when there is no (or only very limited)
peripheral avascular retina remaining. In cases where full retinal vascularization is not
achieved and there are signs of reactivated ROP, however, a sequential approach of first
anti-VEGF therapy for central ROP (in zone I or central zone II) followed by laser therapy
at a later time point for remaining peripheral avascular retina with signs of recurring ROP
activity may be sensible. The crucial question of how systemic changes in VEGF levels after
intravitreal anti-VEGF treatment needs to be addressed and will be discussed in the last
section of this review.
ROP prevention: IGF-supplementation
Prevention is better than treatment – perhaps in particular in ROP. Strict monitoring and low
target saturations for oxygen supplementation during the early weeks of life reduce the risk
of developing severe ROP. However this must be weighed against an increased mortality
risk when oxygen targets are too low [23,24]. Similar to oxygen targets, other factors have
been identified that when levels are optimized may prevent the development of ROP [25].
For example, overall postnatal growth rate is significantly linked to ROP risk [26–33]. A
partial explanation of this observation may be better overall health of an infant with good
postnatal weight gain, while infants with poor postnatal weight gain are more likely to have
other health issues like sepsis or anemia that may indirectly affect ROP development
[34,35]. However, there are also subnormal levels of growth-related factors that may directly
alter ROP risk. This is the case for IGF-1, a growth factor found to be crucial for normal
retinal vascular development [36,37]. Mice deficient for IGF-1 do not develop normal
functional retinal vasculature at the same rate as wild-type controls [37]. This observation is
very relevant to the early stages of postnatal retinal development. As stated above, the
earlier an infant is born, the more avascular retina is present that needs to be vascularized
postnatally in order to prevent the later stages of ROP with preretinal vascular ridge and
pathologic vascular proliferation. If a prematurely born infant lacks optimal IGF-1
postnatally, (s)he will be less likely to achieve a retinal vascular growth rate during the early
weeks of life sufficient to functionally vascularize the retina before ischemia sets in and
promotes excessive amounts of pro-angiogenic growth factors leading to proliferative stages
of ROP.
Unlike VEGF, IGF-1 is a systemic factor that is mainly produced from the liver, reaching
the retina via systemic circulation [38,39]. Lower systemic IGF-1 levels were associated
with a higher risk for ROP [40]. Based on these observations, clinical trials are underway to
evaluate the effect on ROP development of normalizing systemic IGF-1 levels during the
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early postnatal phase to match physiologic levels at that developmental stage if the infant
were still in utero [40]. The phase I trials found that systemic IGF-1 supplementation is
tolerated well by prematurely born infants without observable side effects [40]. Currently, a
phase II study is under way to investigate whether IGF-1 supplementation during the first
weeks of life is safe and well tolerated (clinical trials identifier NCT01096784).
Ideally, the prevention approach of IGF-1 supplementation would be complemented by anti-
VEGF or laser treatment in those infants who fail treatment or miss early intervention.
IGF-1 supplementation would be initiated during the first days of life in all infants at high
risk of ROP and administered up to a gestational age when intrinsic production of IGF-1 was
adequate and when ROP risk was lower. During these first weeks of life (when we never see
the proliferative stages of ROP), the retinal vessels would be supplied with the necessary
IGF-1 to allow functional vascularization of peripheral retina. Coherent with current
screening guidelines, all prematurely born infants would still be screened for ROP from 31–
32 weeks’ PMA onwards. All infants that (with prior IGF-1 supplementation or without)
develop ROP stages requiring treatment would then be treated using either conventional
laser therapy or in appropriate cases intravitreal anti-VEGF therapy, dependent on stage and
zone of ROP and taking into account the individual systemic and ophthalmic condition of
the infant. Overall, this approach would lead to an indivualized treatment regimen in ROP
based on normalizing the infant’s IGF-1 levels and – from 31–32 weeks PMA and onwards
– on the infant’s ROP severity and systemic condition.
Outlook: Open questions and future developments
A big question is whether bevacizumab in the currently used half-adult dose is the ideal anti-
VEGF regimen [41,42]. Lower doses (one quarter or less of the adult dose) may be
sufficient to control ROP disease activitiy [43]. Many commentaries point out the potential
risk of a sustained ocular and systemic VEGF suppression in a developing infant [19,44–46].
Two facts should be emphasized: first, any anti-VEGF drug administered intravitreally will
over time reach the systemic circulation. From adult data, we know that one single
intravitreal bevacizumab injection can suppress systemic VEGF levels for weeks [47,48].
This appears to be also true in infants with ROP [49]. Other anti-VEGF compounds like
ranibizumab have shorter systemic half-lives. While ranibizumab leaves the eye at a similar
rate as bevacizumab, it is cleared much faster from the systemic circulation with a half-life
of hours vs. days [50]. There has never been a pharmacokinetic study (studying half-life and
adequate dose) for anti-VEGF treatment in ROP. The BEAT-ROP study and smaller case
series have used the same half-adult dose [51–53] which suppresses ROP activity in most
infants. It is not known, however, whether infants might be over-treated. Since ROP usually
occurs bilaterally, an infant (often at or below 2 kg body weight) will receive the same
amount of anti-VEGF drug as a 70 kg adult receiving a unilateral injection for age-related
macular degeneration or diabetic macular edema. Per body weight, the infant’s drug
exposure is much higher compared to the adult. In addition, bevacizumab has – due to its
characteristics as a full size antibody – a systemic half-life of several days and can therefore
suppress systemic VEGF levels in a developing infant over many weeks [49].
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These two questions, whether other anti-VEGF compounds with different pharmcodynamic
properties or lower doses might be similarly effective at treating ROP, are currently under
investigation in a multicenter randomized double-blinded investigator initiated trial. This
study, the CARE-ROP trial investigates the effects of two different doses of ranibizumab for
treatment of ROP (NCT02134457). In addition to improved pharmacodynamics with faster
systemic clearance rates for ranibizumab, this drug has been developed explicitly for use in
the eye and is approved for intravitreal use in adults for several indications while
bevacizumab is not approved for use in the eye. In two large government-sponsored
comparative trials between ranibizumab and bevacizumab in adults, comparable ocular
efficacy were found for treatment of age-related macular degeneration [54–57]. It is
therefore likely that ranibizumab will have similar ocular effects as bevacizumab in ROP
while reducing the potential risk of systemic side effects by being cleared rapidly from the
systemic circulation. In addition, the CARE-ROP study will investigate if lower doses (24%
of adult dose) is similarly effective at treating ROP as a higher dose (40% of adult dose).
Both doses are lower than the currently used 50% adult dose of bevacizumab since emerging
data indicate that lower doses might be sufficiently effective at controlling pathologic vessel
formation in ROP while at the same time potentially allowing better functional
vascularization of the peripheral retina with physiologic vessels [43,58]. It will be crucial in
ROP treatment to find the ideal balance between suppression of aberrant pre-retinal vessel
growth while allowing full physiologic intraretinal vascularization of the retina.
Summary
IGF-1 supplementation and anti-VEGF therapy are two novel medical approaches in treating
ROP that have produced promising results in preclinical and clinical studies and have the
potential of revolutionizing the way we treat ROP. The two treatment modalities are
complementary and might in the future provide an individualized treatment regimen for
ROP. IGF-1 supplementation could be a sensible early intervention for preterm infants who
have low systemic IGF-1 levels after birth and during the early weeks of life. Normalization
of systemic IGF-1 levels to values that are physiologic during in utero development at these
ages, could thus offer a preventive treatment strategy that may reduce the incidence of ROP.
For those infants who develop ROP with pathologic vascular activation, however, initiating
IGF-1 supplementation later would not be appropriate. These infants would instead require
treatment aimed at reducing aberrant growth of pre-retinal vessels. This can be achieved by
laser photocoagulation which destroys avascular retinal areas thus eliminating the source of
excessive growth factor production. Alternatively, these later stages could be treated with
targeted elimination of VEGF, the main vascular growth factor being produced in these
avascular retinal areas. Administered in the right dosage and at the right stages, anti-VEGF
treatment has the potential of binding and neutralizing excessive angiogenic growth factor
levels in the vitreous while at the same time allowing physiologic retinal vascularization to
proceed into the peripheral retina thus saving retinal tissue that would have been otherwise
destroyed by laser therapy. For anti-VEGF therapy, however, it has to be ensured that local
and systemic side effects are kept to a minimum. It is therefore of utmost importance to
define the ideal substances and dosages for any pharmacological intervention in ROP.
Stahl et al. Page 6
Neonatology. Author manuscript; available in PMC 2015 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acknowledgments
We are greatful for support from NEI EY022275, EY017017, P01 HD18655, Lowy Medical Research Foundation,
(LEHS) DFG STA1102/5-1 (AS), European Commission FP7 project 305485 PREVENT-ROP (LEHS, AH).
References
1. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the
treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity
randomized trial. Arch Ophthalmol. 2003; 121:1684–1694. [PubMed: 14662586]
2. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis
and angiogenesis. Invest Ophthalmol Vis Sci. 2000; 41:1217–1228. [PubMed: 10752963]
3. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, Seaward MR, Willett KL,
Aderman CM, Guerin KI, Hua J, Lofqvist C, Hellstrom A, Smith LE. The mouse retina as an
angiogenesis model. Invest Ophthalmol Vis Sci. 2010; 51:2813–2826. [PubMed: 20484600]
4. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1
and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology.
2008; 115:1065–1070. e1061. [PubMed: 18031819]
5. Velez-Montoya R, Clapp C, Rivera JC, Garcia-Aguirre G, Morales-Canton V, Fromow-Guerra J,
Guerrero-Naranjo JL, Quiroz-Mercado H. Intraocular and systemic levels of vascular endothelial
growth factor in advanced cases of retinopathy of prematurity. Clin Ophthalmol. 2010; 4:947–953.
[PubMed: 20856587]
6. Jandeck C, Stahl A. retinopathy of prematurity. Klin Monbl Augenheilkd. 2012; 229:559–575. quiz
576-557. [PubMed: 22592347]
7. Jandeck C, Kellner U, Lorenz B, Seiberth V. guidelines for ophthalmological screening of
premature infants in germany. Klin Monbl Augenheilkd. 2008; 225:123–130. [PubMed: 18293263]
8. Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for
retinopathy of prematurity. Three-month outcome. Arch Ophthalmol. 1990; 108:195–204.
[PubMed: 2405827]
9. Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for
retinopathy of prematurity. One-year outcome--structure and function. Arch Ophthalmol. 1990;
108:1408–1416. [PubMed: 2222274]
10. McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+
retinopathy of prematurity. Ophthalmology. 1991; 98:576–580. [PubMed: 2062488]
11. Landers MB 3rd, Toth CA, Semple HC, Morse LS. Treatment of retinopathy of prematurity with
argon laser photocoagulation. Arch Ophthalmol. 1992; 110:44–47. [PubMed: 1731722]
12. Fleming TN, Runge PE, Charles ST. Diode laser photocoagulation for prethreshold, posterior
retinopathy of prematurity. Am J Ophthalmol. 1992; 114:589–592. [PubMed: 1443021]
13. Simpson JL, Melia M, Yang MB, Buffenn AN, Chiang MF, Lambert SR. Current role of
cryotherapy in retinopathy of prematurity: A report by the american academy of ophthalmology.
Ophthalmology. 2012; 119:873–877. [PubMed: 22381808]
14. Choi J, Kim JH, Kim SJ, Yu YS. Long-term results of lens-sparing vitrectomy for progressive
posterior-type stage 4a retinopathy of prematurity. Korean J Ophthalmol. 2012; 26:277–284.
[PubMed: 22870027]
15. Repka MX, Tung B, Good WV, Capone A Jr, Shapiro MJ. Outcome of eyes developing retinal
detachment during the early treatment for retinopathy of prematurity study. Arch Ophthalmol.
2011; 129:1175–1179. [PubMed: 21911664]
16. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+
retinopathy of prematurity. N Engl J Med. 2011; 364:603–615. [PubMed: 21323540]
17. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of
prematurity after bevacizumab injection. Arch Ophthalmol. 2012; 130:1000–1006. [PubMed:
22491394]
Stahl et al. Page 7
Neonatology. Author manuscript; available in PMC 2015 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
18. Lee BJ, Kim JH, Heo H, Yu YS. Delayed onset atypical vitreoretinal traction band formation after
an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond). 2012;
26:903–909. quiz 910. [PubMed: 22699977]
19. Hard AL, Hellstrom A. On the use of antiangiogenetic medications for retinopathy of prematurity.
Acta Paediatr. 2011; 100:1063–1065. [PubMed: 21517962]
20. Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal
bevacizumab for retinopathy of prematurity: Refractive error results. Am J Ophthalmol. 2013;
155:1119–1124. e1111. [PubMed: 23490192]
21. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G,
Guerrero-Naranjo JL, Chan RV, Quiroz-Mercado H. Long-term effect of antiangiogenic therapy
for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013; 33:329–338. [PubMed:
23099498]
22. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection
of 1.5 mg versus 3. 0 mg of bevacizumab in humans. Retina. 2011; 31:1877–1884. [PubMed:
21738089]
23. Stenson BJ. Oxygen targets for preterm infants. Neonatology. 2013; 103:341–345. [PubMed:
23736013]
24. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and
severe retinopathy of prematurity: A meta-analysis. Pediatrics. 2010; 125:e1483–1492. [PubMed:
20498174]
25. Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity.
Neonatology. 2011; 100:116–129. [PubMed: 21372594]
26. Fortes Filho JB, Bonomo PP, Maia M, Procianoy RS. Weight gain measured at 6 weeks after birth
as a predictor for severe retinopathy of prematurity: Study with 317 very low birth weight preterm
babies. Graefes Arch Clin Exp Ophthalmol. 2009; 247:831–836. [PubMed: 19052770]
27. Hellstrom A, Ley D, Hansen-Pupp I, Niklasson A, Smith L, Lofqvist C, Hard AL. New insights
into the development of retinopathy of prematurity--importance of early weight gain. Acta
Paediatr. 2010; 99:502–508. [PubMed: 19878131]
28. Lofqvist C, Andersson E, Sigurdsson J, Engstrom E, Hard AL, Niklasson A, Smith LE, Hellstrom
A. Longitudinal postnatal weight and insulin-like growth factor i measurements in the prediction
of retinopathy of prematurity. Arch Ophthalmol. 2006; 124:1711–1718. [PubMed: 17159030]
29. Lofqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LE, Ley D, Hellstrom A. Validation of a
new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and
insulinlike growth factor i. Arch Ophthalmol. 2009; 127:622–627. [PubMed: 19433710]
30. Stahl A, Chen J, Sapieha P, Seaward MR, Krah NM, Dennison RJ, Favazza T, Bucher F, Lofqvist
C, Ong H, Hellstrom A, Chemtob S, Akula JD, Smith LE. Postnatal weight gain modifies severity
and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;
177:2715–2723. [PubMed: 21056995]
31. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: A risk factor for severe
retinopathy of prematurity. J AAPOS. 2000; 4:343–347. [PubMed: 11124668]
32. Wu C, Lofqvist C, Smith LE, Vanderveen DK, Hellstrom A. Importance of early postnatal weight
gain for normal retinal angiogenesis in very preterm infants: A multicenter study analyzing weight
velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2012
33. Wu C, Vanderveen DK, Hellstrom A, Lofqvist C, Smith LE. Longitudinal postnatal weight
measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2010; 128:443–
447. [PubMed: 20385939]
34. Tolsma KW, Allred EN, Chen ML, Duker J, Leviton A, Dammann O. Neonatal bacteremia and
retinopathy of prematurity: The elgan study. Arch Ophthalmol. 2011; 129:1555–1563. [PubMed:
22159674]
35. Weintraub Z, Carmi N, Elouti H, Rumelt S. The association between stage 3 or higher retinopathy
of prematurity and other disorders of prematurity. Can J Ophthalmol. 2011; 46:419–424.
[PubMed: 21995985]
36. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M,
Svensson E, Smith L, Weinberger D, Albertsson Wikland K, Laron Z. Igf-i is critical for normal
Stahl et al. Page 8
Neonatology. Author manuscript; available in PMC 2015 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
vascularization of the human retina. J Clin Endocrinol Metab. 2002; 87:3413–3416. [PubMed:
12107259]
37. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B,
Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE. Low igf-i suppresses vegf-survival
signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity.
Proc Natl Acad Sci U S A. 2001; 98:5804–5808. [PubMed: 11331770]
38. Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum WF, Schatz H, Pfeiffer
AF. Systemic levels contribute significantly to increased intraocular igf-i, igf-ii and igf-bp3
[correction of ifg-bp3] in proliferative diabetic retinopathy. Horm Metab Res. 2000; 32:196–200.
[PubMed: 10871161]
39. Engstrom E, Niklasson A, Wikland KA, Ewald U, Hellstrom A. The role of maternal factors,
postnatal nutrition, weight gain, and gender in regulation of serum igf-i among preterm infants.
Pediatric research. 2005; 57:605–610. [PubMed: 15695599]
40. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, Lofqvist C,
Svensson E, Holm S, Ewald U, Holmstrom G, Smith LE. Postnatal serum insulin-like growth
factor i deficiency is associated with retinopathy of prematurity and other complications of
premature birth. Pediatrics. 2003; 112:1016–1020. [PubMed: 14595040]
41. Avery RL. Bevacizumab (avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or
both? J AAPOS. 2012; 16:2–4. [PubMed: 22237669]
42. Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of
prematurity? Acta Ophthalmol. 2013; 91:e154. [PubMed: 22989079]
43. Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for
retinopathy of prematurity. Acta Ophthalmol. 2013
44. Lim LS, Mitchell P, Wong TY. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;
364:2360. author reply 2361–2362. [PubMed: 21675897]
45. Gilbert CE, Zin A, Darlow B. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;
364:2359–2360. author reply 2361-2352. [PubMed: 21675898]
46. Good WV, Palmer EA. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;
364:2359. author reply 2361–2352. [PubMed: 21675899]
47. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular
endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and
pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular
oedema. Br J Ophthalmol. 2013; 97:454–459. [PubMed: 23385630]
48. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of
vascular endothelial growth factor and pigment epithelium-derived factor before and after
intravitreal injection of bevacizumab. Br J Ophthalmol. 2010; 94:1215–1218. [PubMed:
20538658]
49. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum
concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with
retinopathy of prematurity. Am J Ophthalmol. 2012; 153:327–333. e321. [PubMed: 21930258]
50. Krohne TU, Holz FG, Meyer CH. pharmacokinetics of intravitreally administered vegf inhibitors.
Ophthalmologe. 2014; 111:113–120. [PubMed: 24346958]
51. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal
bevacizumab (avastin). Retina. 2010; 30:S24–31. [PubMed: 20224475]
52. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA.
Off-label use of intravitreal bevacizumab (avastin) for salvage treatment in progressive threshold
retinopathy of prematurity. Retina. 2008; 28:S13–18. [PubMed: 18317338]
53. Nazari H, Modarres M, Parvaresh MM, Ghasemi Falavarjani K. Intravitreal bevacizumab in
combination with laser therapy for the treatment of severe retinopathy of prematurity (rop)
associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;
248:1713–1718. [PubMed: 20582706]
54. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL
3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular
degeneration: Two-year results. Ophthalmology. 2012; 119:1388–1398. [PubMed: 22555112]
Stahl et al. Page 9
Neonatology. Author manuscript; available in PMC 2015 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
55. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and
bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897–
1908. [PubMed: 21526923]
56. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC.
Alternative treatments to inhibit vegf in age-related choroidal neovascularisation: 2-year findings
of the ivan randomised controlled trial. Lancet. 2013; 382:1258–1267. [PubMed: 23870813]
57. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year
findings from the ivan randomized trial. Ophthalmology. 2012; 119:1399–1411. [PubMed:
22578446]
58. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of vegf trap on normal retinal vascular
development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;
52:4039–4047. [PubMed: 21357392]
Stahl et al. Page 10
Neonatology. Author manuscript; available in PMC 2015 October 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Retinal vessels (red) grow in a centrifugal pattern from the optic nerve head towards the
periphery of the reina, the ora serrata. In the mouse retina, retinal vascular growth occurs
postnatally between postnatal day (P) 1 and 8 under normoxic (N) conditions (referred to as
P1N – P8N in the Figure). In normal human development, Retinal vascularization occurs in
utero and the retina is fully vascularized at term. However, when development is disrupted
by preterm birth retinal vascular development can be severely suppressed or developed
vessels can regress leading to ROP. Image reprinted with permission from [3] (Copyright
holder: Association for Research in Vision and Ophthalmology).
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Figure 2.
Retinal zones used for grading of ROP. Zone I describes a circle around the optic nerve head
(ONH) with a radius of twice the distance from ONH to fovea. Zone II is a circle around the
ONH reaching the nasal periphery (at the 3 o’clock position in the image). Zone III is the
remaining temporal crescent-shaped retina. Image reproduced with permission from [6].
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